Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano...Read more
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity...Read more
Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity Combination generated complete responses...Read more
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the Company’s Phase 1b study evaluating VYN202 for...Read more
TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks. If approved, TrenibotE will be the first neurotoxin of its kind...Read more
LA JOLLA, Calif. / Apr 24, 2025 / Business Wire / Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received...Read more
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 24.85 2.89 | $884.58 |
| argenx | 14.25 2.37 | $614.76 |
| Encompass Health | 11.96 11.79 | $113.37 |
| Chemed | 8.96 1.64 | $555.74 |
| Alnylam Pharmaceuticals | 8.95 3.69 | $251.56 |
| Madrigal Pharmaceuticals | 6.86 2.14 | $326.79 |
| Aclarion | 6.76 901.33 | $7.51 |
| McKesson | 6.57 0.95 | $695.00 |
| Intuitive | 6.46 1.27 | $514.59 |
| Stryker | 4.01 1.11 | $365.06 |
| West Pharmaceutical | 3.96 1.88 | $214.55 |
| Ascendis Pharma | 3.70 2.31 | $164.15 |
| Merck | 2.90 3.63 | $82.74 |
| Regeneron Pharmaceuticals | 2.88 0.48 | $602.64 |
| OpGen | 2.87 151.05 | $4.77 |
| Jaguar Health | 2.84 35.24 | $10.90 |
| Addus HomeCare | 2.54 2.59 | $100.58 |
| Semler Scientific | 2.40 6.97 | $36.84 |
| Company | Volume | Last Trade |
|---|---|---|
| Sharps Technology | 74,222,588 | $0.02 |
| Azitra | 42,561,658 | $0.31 |
| China SXT Pharmaceuticals | 37,822,363 | $2.37 |
| Pfizer | 34,342,718 | $22.92 |
| Merck | 27,387,547 | $82.74 |
| Summit Therapeutics | 24,375,957 | $23.17 |
| Acrivon Therapeutics | 15,994,031 | $1.64 |
| Bristol-Myers Squibb | 15,963,969 | $47.90 |
| Gilead Sciences | 14,007,265 | $103.17 |
| Insmed | 13,585,902 | $69.69 |
| Novavax | 13,014,900 | $6.67 |
| Recursion | 12,600,429 | $5.69 |
| Iovance Biotherapeutics | 12,413,776 | $3.51 |
| AbbVie | 10,352,092 | $186.47 |
| PacBio | 9,662,403 | $1.11 |
| Viatris | 9,097,427 | $8.13 |
| UnitedHealth | 9,010,635 | $418.98 |
| Tempus AI | 8,942,642 | $52.87 |
| Centene | 8,408,467 | $57.44 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
